Fig. 4
From: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Activation of antibody-dependent cellular cytotoxicity (ADCC) by nivolumab, pembrolizumab and prolgolimab. PBMCs were pre-activated with SEB. (A) Evaluation of antibody binding to FcγRIIIa in a reporter bioassay. (B) ADCC assessment in the cytotoxicity test with NK cells.
